Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUPINE: Lurbinectedin plus paclitaxel vs paclitaxel in previously treated small cell lung cancer
KCT0011405Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Mar 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin, paclitaxel in small cell lung cancer (SCLC), small cell carcinoma (SCC), sponsored by Boryung. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
lurbinectedinpaclitaxel
03
Conditions
small cell lung cancer (SCLC)small cell carcinoma (SCC)
Beyond the preview
Go deeper on KCT0011405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011405.